These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Pharmacokinetics of L-dopa in patients with Parkinson's disease. Mena MA, Muradas V, Bazan E, Reiriz J, de Yebenes JG. Adv Neurol; 1987 Feb; 45():481-6. PubMed ID: 2950730 [No Abstract] [Full Text] [Related]
3. Levodopa with benserazide or carbidopa in Parkinson disease. Rinne UK, Mölsä P. Neurology; 1979 Dec; 29(12):1584-9. PubMed ID: 574221 [Abstract] [Full Text] [Related]
4. [Combined treatment of Parkinsonism with L-dopa and peripheral dopa decarboxylase inhibitors--clinical course of 13 cases and levels of serum/dopa and dopamine]. Mizuno Y, Yoshida M, Obayashi T, Ueki A. Rinsho Shinkeigaku; 1976 Jul 01; 16(7):511-9. PubMed ID: 986921 [No Abstract] [Full Text] [Related]
5. [Decarboxylase inhibitors combined with L-dopa in the treatment of Parkinson's disease]. Rondot P. Rev Prat; 1974 Mar 11; 24(15):1211-2, 1215-6, 1219. PubMed ID: 4416964 [No Abstract] [Full Text] [Related]
7. Patient benefits of l-dopa and a decarboxylase inhibitor in the treatment of Parkinson's disease in elderly patients. Admani AK, Verma S, Cordingley GJ, Harris RI. Pharmatherapeutica; 1985 Nov 11; 4(2):132-40. PubMed ID: 4059292 [Abstract] [Full Text] [Related]
8. Parkinson's disease: new treatments. Stewart RM. Compr Ther; 1981 Apr 11; 7(4):38-44. PubMed ID: 7237986 [Abstract] [Full Text] [Related]
9. [Development of studies on the treatment of parkinsonian syndromes with levodopa. II. Long-term effects of L-DOPA alone or in combination with a decarboxylase inhibitor]. Rabadeau Dumas JL, Rondot P, Cardon P. Therapie; 1977 Apr 11; 32(2):161-72. PubMed ID: 898124 [No Abstract] [Full Text] [Related]
10. Problems arising during chronic treatment with L-dopa for Parkinson's disease: changes in response to treatment. Caraceni TA, Girotti F, Giovannini P, Parati E. J Neural Transm Suppl; 1986 Apr 11; 22():189-99. PubMed ID: 3537210 [Abstract] [Full Text] [Related]
11. [Value of low-dose dopa therapy in Parkinson disease]. Petit H, Rousseaux M, Mazingue A, Warot P. LARC Med; 1983 Apr 11; 3(7):514-6. PubMed ID: 6645742 [No Abstract] [Full Text] [Related]
12. Levodopa + carbidopa + entacapone. Entacapone: a second look: new preparations. Parkinson's disease: a modest effect. Prescrire Int; 2005 Apr 11; 14(76):51-4. PubMed ID: 15875340 [Abstract] [Full Text] [Related]
13. Treatment of Parkinson's disease. Lieberman A. Curr Opin Neurol Neurosurg; 1993 Jun 11; 6(3):339-43. PubMed ID: 8507903 [Abstract] [Full Text] [Related]
15. Levodopa treatment of Parkinson's syndrome: past and future. Pletscher A. Adv Neurol; 1990 Jun 11; 53():469-73. PubMed ID: 2239486 [No Abstract] [Full Text] [Related]
16. Dystonia--L-dopa responsive or juvenile parkinsonism? Rondot P, Ziegler M. J Neural Transm Suppl; 1983 Jun 11; 19():273-81. PubMed ID: 6583312 [Abstract] [Full Text] [Related]
17. Combined use of benserazide and carbidopa in Parkinson's disease. Lieberman AN, Goldstein M, Gopinathan G, Neophytides A, Hiesiger E, Walker R, Nelson J. Neurology; 1984 Feb 11; 34(2):227-9. PubMed ID: 6538015 [Abstract] [Full Text] [Related]